Holen Sie sich die Stockscreener-App
16.16
0.62%
-0.10
Handel nachbörslich:
16.16
Schlusskurs vom Vortag:
$16.26
Offen:
$16.3
24-Stunden-Volumen:
728.92K
Relative Volume:
1.30
Marktkapitalisierung:
$974.05M
Einnahmen:
$1.23M
Nettoeinkommen (Verlust:
$-214.90M
KGV:
-3.9202
EPS:
-4.1222
Netto-Cashflow:
$-151.25M
1W Leistung:
-4.83%
1M Leistung:
+2.54%
6M Leistung:
-31.81%
1J Leistung:
-38.30%
1-Tages-Spanne:
$15.81
$17.01
1-Wochen-Bereich:
$15.81
$17.70
52-Wochen-Spanne:
$10.91
$40.26
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Firmenname
Spyre Therapeutics Inc
Sektor
Branche
Telefon
(617) 651-5940
Adresse
221 CRESCENT STREET, WALTHAM
Vergleichen Sie SYRE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
16.16 | 981.35M | 1.23M | -214.90M | -151.25M | -4.1222 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 118.67B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.54 | 59.23B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
419.56 | 52.67B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
690.32 | 41.24B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
304.30 | 32.36B | 3.81B | -644.79M | -669.77M | -6.24 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-08 | Eingeleitet | Leerink Partners | Outperform |
| 2025-03-18 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-04 | Eingeleitet | Wedbush | Outperform |
| 2024-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-05-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-12-11 | Eingeleitet | Guggenheim | Buy |
| 2023-12-11 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-09-04 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-14 | Bestätigt | Needham | Buy |
Alle ansehen
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
Spyre Therapeutics Inc. Uptrend in Early Stages Indicators Say YesDaily Smart Money Movement Monitor Activated - beatles.ru
Using AI based signals to follow Spyre Therapeutics Inc.Summary of Reliable Long-Term Trade Models - Newser
Combining machine learning predictions for Spyre Therapeutics Inc.Weekly Setup Summary for Risk Controlled Trades - Newser
How does Spyre Therapeutics Inc. compare to its industry peersGet daily expert analysis on top stocks - Jammu Links News
Using flow based indicators on Spyre Therapeutics Inc.Stock Portfolio Risk and Return Analysis - Newser
Should I hold or sell Spyre Therapeutics Inc. stock in 2025Achieve breakthrough profits with expert advice - Jammu Links News
Is it the right time to buy Spyre Therapeutics Inc. stockBuild wealth with steady, reliable stocks - Jammu Links News
What is the dividend policy of Spyre Therapeutics Inc. stockExponential return rates - Jammu Links News
Is Spyre Therapeutics Inc. stock overvalued or undervaluedMarket-leading growth rates - Jammu Links News
What catalysts could drive Spyre Therapeutics Inc. stock higher in 2025Get exclusive market insights for better trading - Jammu Links News
What are analysts’ price targets for Spyre Therapeutics Inc. in the next 12 monthsInvest in high-yield stocks with confidence - Jammu Links News
Will a bounce in Spyre Therapeutics Inc. offer an exitFree Entry Alert With Low Drawdown Strategy - Newser
What makes Spyre Therapeutics Inc. stock price move sharplyBuild a diversified portfolio for risk management - Jammu Links News
What moving averages say about Spyre Therapeutics Inc.Price Forecast Based on AI Analysis - Newser
What are the technical indicators suggesting about Spyre Therapeutics Inc.High-octane financial growth - Jammu Links News
How hedge fund analytics apply to Spyre Therapeutics Inc. stockFree Trade Insight With Community Collaboration - Newser
Market reaction to Spyre Therapeutics Inc.’s recent newsTrade Alert System with Volume Analysis - Newser
Visual trend scoring systems applied to Spyre Therapeutics Inc.Machine Learning Stock Price Forecast Tool - Newser
Is Spyre Therapeutics Inc. a growth stock or a value stockFree Stock Alerts For Every Investor - Jammu Links News
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre Therapeutics Announces Grants of Inducement Awards - GlobeNewswire Inc.
Intraday pattern recognizer results for Spyre Therapeutics Inc.Free Multi-Bagger Potential Stock Forecast Tools - Newser
Analyzing drawdowns of Spyre Therapeutics Inc. with statistical toolsTechnical Reversal Setup with Risk Limits - Newser
Identifying reversal signals in Spyre Therapeutics Inc.ROI Focused Setup Screener With Exit Markers - Newser
Moving Average Trends for Spyre Therapeutics Inc. Stock: What They IndicateBuy Point Strategy with Profit Protection - Newser
How strong is Spyre Therapeutics Inc. company’s balance sheetBreakout Stocks Tracker For Consistent Profits - Jammu Links News
Why Spyre Therapeutics Inc. stock attracts strong analyst attentionFree Access to Real-Time Trade Insights - Newser
Can momentum traders help lift Spyre Therapeutics Inc.Short-Term Bounce Forecast for Oversold Stocks - Newser
Spyre Therapeutics Inc. stock trend outlook and recovery pathBuy Signal System Based on Price Action - Newser
How to track smart money flows in Spyre Therapeutics Inc.Buy Signal System Based on Price Action - Newser
Sector ETF Data Correlates with Strength in Spyre Therapeutics Inc.Intraday Trend Analysis for Fast Gains Released - metal.it
Trading Bots Trigger Alerts on Spyre Therapeutics Inc. ActivityCapital Growth With Controlled Risk Picks Suggested - metal.it
How Resilient Is Spyre Therapeutics Inc. Stock During Economic DownturnsChart Breakout Buy Signal Detection Confirmed - metal.it
Published on: 2025-07-29 08:11:08 - metal.it
Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):